BioSpace News Archive

The Annual General Meeting of Nordic Nanovector ASA was held on 28 April 2022 in Oslo, Norway.

Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the first visit of the first patient in the TOTUM•63 mode of action clinical study conducted by the Laval University Institute of Nutrition and Functional Foods (INAF) in Quebec City, in partnership with Nestlé Health Science.

Biovica, active in cancer diagnostics, announces that the company has submitted its updated 510-application to the U.S. Food and Drug Administration to receive marketing authorization for the blood-based biomarker assay DiviTum®TKa.

Abivax SA announces the publication of its 2022 Universal Registration Document, filed with the French Financial Market Authorities, Autorité des Marchés Financiers, on April 28, 2022.

Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced two abstracts accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Immunicom, Inc., a clinical-stage biotechnology company developing a breakthrough technology platform for immuno-oncology, presented data from its ongoing clinical investigation, Protocol CP7-005 [NCT04004910], at the American Association for Cancer Research (AACR) Annual Conference in New Orleans.

Innovative MedTech, Inc. (the “Company”) (OTC: IMTH), a provider of health and wellness services, today announced that it has signed a share exchange agreement to acquire RX Vitality, Inc. (“RX Vitality”), a media and finance advisory company, in a stock transaction.

Viridos has been awarded the prestigious California Competes Grant by the Governor’s Office of Business and Economic Development.

The global biopharmaceutical third party logistics market size was valued at US$ 100.23 billion in 2021 and is projected to reach around US$ 159.86 billion by 2030, growing at a CAGR of 5.3% from 2022 to 2030.

According to Report, the digital biomarkers market is anticipated to garner notable gains, registering a CAGR of 28.1% from 2022 to 2030to reach around US$ 14.58 billion by 2030.